Alzheimer's agitation drug safety trial ends early
NCT ID NCT06736509
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested the long-term safety of AXS-05, a combination of dextromethorphan and bupropion, for treating agitation in people with Alzheimer's disease. It enrolled 139 participants who had completed earlier studies. The trial was terminated early, so the full safety picture is incomplete.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
AXS-05 (dextromethorphan and bupropion combination tablet)
What this could lead to
If successful, this could provide a long-term treatment option to safely manage agitation in people with Alzheimer's disease.
What could go wrong
The study was terminated early, so results are limited. It was an open-label extension, meaning no placebo group, which can make safety findings less reliable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Clinical Research Site
Peoria, Arizona, 85381, United States
-
Clinical Research Site
Walnut Creek, California, 94596, United States
-
Clinical Research Site
Bonita Springs, Florida, 34134, United States
-
Clinical Research Site
Brandon, Florida, 33511, United States
-
Clinical Research Site
Greenacres City, Florida, 33467, United States
-
Clinical Research Site
Hialeah, Florida, 33012, United States
-
Clinical Research Site
Miami, Florida, 33126, United States
-
Clinical Research Site
Miami, Florida, 33145, United States
-
Clinical Research Site
Miami, Florida, 33155, United States
-
Clinical Research Site
Miami, Florida, 33165, United States
-
Clinical Research Site
Miami, Florida, 33173, United States
-
Clinical Research Site
Miami Gardens, Florida, 33014, United States
-
Clinical Research Site
Miami Lakes, Florida, 33014, United States
-
Clinical Research Site
Pembroke Pines, Florida, 33025, United States
-
Clinical Research Site
Tampa, Florida, 33614, United States
-
Clinical Research Site
Tampa, Florida, 33634, United States
-
Clinical Research Site
Braintree, Massachusetts, 02184, United States
-
Clinical Research Site
Brooklyn, New York, 11229, United States
-
Clinical Research Site
Charlotte, North Carolina, 28211, United States
-
Clinical Research Site
Mesquite, Texas, 75149, United States
-
Clinical Research Site
Arlington, Virginia, 22205, United States
-
Clinical Research Site
San Juan, 00918, Puerto Rico